This medical condition has either been superseded or has become inactive
Specific Conditions |
|
Indication for Ig Use |
|
Level of Evidence | Clear evidence of benefit (Category 1) |
Description and Diagnostic Criteria |
GBS is the commonest cause of acute flaccid paralysis in the West. The syndrome typically presents with rapidly progressive, relatively symmetrical ascending limb weakness consistent with a polyradiculoneuropathy and often with associated cranial nerve involvement. Motor signs and symptoms usually predominate over sensory signs and symptoms. Loss of tendon reflexes occurs in most cases. Major complications include respiratory failure and autonomic dysfunction. The disease is monophasic, reaching its nadir usually within two weeks, although arbitrary definition accepts a limit of four weeks. A plateau phase of variable duration follows the nadir before gradual recovery. Although recovery is generally good or complete in the majority of patients, persistent disability has been reported to occur in about 20% and death in 4 to 15% of patients. Intravenous immunoglobulin (IVIg) has been shown to have the same efficacy as plasma exchange. The choice is based on availability, practicality, convenience, cost, and ease or safety of administration (Asia–Pacific IVIg Advisory Group). Investigations There is no biological marker for GBS. It is diagnosed by clinical recognition of rapidly evolving paralysis with areflexia. Investigations include the following:
|
Justification for Evidence Category |
One systematic review of nine randomised controlled trials (RCTs) of moderate quality found IVIg hastened recovery in adults with GBS to the same degree as plasma exchange (Biotext 2004). One low-quality RCT with a small sample size (n = 21), in which the randomisation of patients to the IVIg treatment group was skewed, was identified. Children who received IVIg treatment showed earlier signs of improvement, and disability scores were lower at four weeks than the placebo group (Frommer and Madronio 2006). |
Qualifying Criteria for Ig Therapy |
AND
|
Review Criteria for Assessing the Effectiveness of Ig Use |
Clinical effectiveness of Ig therapy may be demonstrated by:
|
Dose |
Approximately 10% of patients relapse, which may require a second treatment with IVIg. A second dose must only be on the advice of and after assessment by a Neurologist. Refer to the current product information sheet for further information. |
Bibliography |
---|
Association of British Neurologists 2005, Guidelines for the use of intravenous immunoglobulin in neurological diseases, The Association, London. Available from: http://www.theabn.org/media/docs/ABN%20publications/IVIg-guidelines-final-July05.pdf Biotext 2004, ‘Summary data on conditions and papers’, in A systematic literature review and report on the efficacy of intravenous immunoglobulin therapy and its risks, commissioned by the National Blood Authority on behalf of all Australian Governments, pp.149–50. Available from: http://www.nba.gov.au/pubs/pdf/report-lit-rev.pdf Frommer, M & Madronio, C 2006, The use of intravenous immunoglobulin in Australia. A report for the National Blood Authority, Part B: systematic literature review, Sydney Health Projects Group, University of Sydney, Sydney, pp. 32–4. Hughes, RAC, Raphaël, J-C, Swan, AV, et al 2006, ‘Intravenous immunoglobulin for Guillain– Barré syndrome (Cochrane Review)’, in The Cochrane Library, Issue 1, John Wiley & Sons, Ltd, Chichester, United Kingdom. Korinthenberg, R, Schessl, J, Kirschner, J, et al 2005, 'Intravenously administered immunoglobulin in the treatment of childhood Guillain–Barré syndrome: a randomized trial’, Paediatrics, vol. 116, no. 1, pp. 8–14. Kornberg, AJ, for the Asia–Pacific IVIg Advisory Board 2004, Bringing consensus to the use of IVIg in neurology. Expert consensus statements on the use of IVIg in neurology, 1st edn, Asia–Pacific IVIg Advisory Board, Melbourne, pp. 14–20. |